233 related articles for article (PubMed ID: 19633050)
1. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
Sonpavde G; Periman PO; Bernold D; Weckstein D; Fleming MT; Galsky MD; Berry WR; Zhan F; Boehm KA; Asmar L; Hutson TE
Ann Oncol; 2010 Feb; 21(2):319-324. PubMed ID: 19633050
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
Zurita AJ; George DJ; Shore ND; Liu G; Wilding G; Hutson TE; Kozloff M; Mathew P; Harmon CS; Wang SL; Chen I; Chow Maneval E; Logothetis CJ
Ann Oncol; 2012 Mar; 23(3):688-694. PubMed ID: 21821830
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of sunitinib in men with advanced prostate cancer.
Dror Michaelson M; Regan MM; Oh WK; Kaufman DS; Olivier K; Michaelson SZ; Spicer B; Gurski C; Kantoff PW; Smith MR
Ann Oncol; 2009 May; 20(5):913-20. PubMed ID: 19403935
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.
Sonpavde G; Hutson TE; Berry WR; Boehm KA; Asmar L
Clin Genitourin Cancer; 2008 Sep; 6(2):134-7. PubMed ID: 18824440
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
Parimi S; Eliasziw M; North S; Trudeau M; Winquist E; Chi KN; Ruether D; Cheng T; Eigl BJ
Invest New Drugs; 2016 Dec; 34(6):771-776. PubMed ID: 27565809
[TBL] [Abstract][Full Text] [Related]
6. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Castellano D; González-Larriba JL; Antón-Aparicio LM; Cassinello J; Grande E; Esteban E; Sepúlveda J
Expert Opin Pharmacother; 2011 Nov; 12(16):2433-9. PubMed ID: 21671835
[TBL] [Abstract][Full Text] [Related]
7. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Michaelson MD; Oudard S; Ou YC; Sengeløv L; Saad F; Houede N; Ostler P; Stenzl A; Daugaard G; Jones R; Laestadius F; Ullèn A; Bahl A; Castellano D; Gschwend J; Maurina T; Chow Maneval E; Wang SL; Lechuga MJ; Paolini J; Chen I
J Clin Oncol; 2014 Jan; 32(2):76-82. PubMed ID: 24323035
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
Garcia JA; Hutson TE; Shepard D; Elson P; Dreicer R
Cancer; 2011 Feb; 117(4):752-7. PubMed ID: 20922803
[TBL] [Abstract][Full Text] [Related]
9. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
[TBL] [Abstract][Full Text] [Related]
10. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer.
Khasraw M; Pavlakis N; McCowatt S; Underhill C; Begbie S; de Souza P; Boyce A; Parnis F; Lim V; Harvie R; Marx G
Ann Oncol; 2010 Jun; 21(6):1302-1307. PubMed ID: 19917571
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer.
Heidenreich A; Rawal SK; Szkarlat K; Bogdanova N; Dirix L; Stenzl A; Welslau M; Wang G; Dawkins F; de Boer CJ; Schrijvers D
Ann Oncol; 2013 Feb; 24(2):329-336. PubMed ID: 23104724
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
Ning YM; Gulley JL; Arlen PM; Woo S; Steinberg SM; Wright JJ; Parnes HL; Trepel JB; Lee MJ; Kim YS; Sun H; Madan RA; Latham L; Jones E; Chen CC; Figg WD; Dahut WL
J Clin Oncol; 2010 Apr; 28(12):2070-6. PubMed ID: 20308663
[TBL] [Abstract][Full Text] [Related]
13. A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer.
Michels J; Ellard SL; Le L; Kollmannsberger C; Murray N; Tomlinson Guns ES; Carr R; Chi KN
Ann Oncol; 2010 Feb; 21(2):305-311. PubMed ID: 19633045
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
15. [Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel].
Gasent JM; Grande E; Casinello J; Provencia M; Laforga JB; Alberola V
Actas Urol Esp; 2011 Jan; 35(1):57-60. PubMed ID: 21256396
[TBL] [Abstract][Full Text] [Related]
16. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
17. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
Hervonen P; Tulijoki T; Kellokumpu-Lehtinen P
Anticancer Res; 2012 Aug; 32(8):3305-9. PubMed ID: 22843906
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.
Schneider BJ; Gadgeel SM; Ramnath N; Wozniak AJ; Dy GK; Daignault S; Kalemkerian GP
J Thorac Oncol; 2011 Jun; 6(6):1117-20. PubMed ID: 21512407
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
Buonerba C; Federico P; D'Aniello C; Rescigno P; Cavaliere C; Puglia L; Ferro M; Altieri V; Perdonà S; De Placido S; Di Lorenzo G
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
Armstrong AJ; Halabi S; Healy P; Lee WR; Koontz BF; Moul JW; Mundy K; Creel P; Wood S; Davis K; Carducci MA; Stein M; Hobbs C; Reimer B; Nguyen M; Anand M; Bratt L; Kim S; Tran PT; George DJ;
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):100-6. PubMed ID: 26754260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
